319 related articles for article (PubMed ID: 32499905)
1. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
[TBL] [Abstract][Full Text] [Related]
2. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
3. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
Noguchi K; Ikawa Y
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
6. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
Heidegger S; Beer AJ; Geissinger E; Rosenwald A; Peschel C; Ringshausen I; Keller U
Onco Targets Ther; 2014; 7():1123-7. PubMed ID: 25018638
[TBL] [Abstract][Full Text] [Related]
8. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
10. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
12. ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase".
Lu Y; Zhao X; Wang E; Chen W; Huang Q
Leuk Res; 2010 Apr; 34(4):475-82. PubMed ID: 19695703
[TBL] [Abstract][Full Text] [Related]
13. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
[TBL] [Abstract][Full Text] [Related]
14. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
16. [Long-term administration of brentuximab vedotin in a patient with primary cutaneous anaplastic large cell lymphoma with peripheral blood involvement with leukemic change].
Kumekawa H; Mizuchi D; Iiyama M
Rinsho Ketsueki; 2018; 59(2):187-190. PubMed ID: 29515072
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
18. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
[TBL] [Abstract][Full Text] [Related]
20. Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report.
Harrer DC; Menhart K; Mayer S; Herr W; Reichle A; Vogelhuber M
Front Oncol; 2020; 10():585830. PubMed ID: 33134180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
